Gene Therapies: What’s to Come as The Industry Moves Forward

Welcome to Episode 1 of The Life Science Report. In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life Science Advisors to discuss the field of gene therapies and insights from their recently authored piece in Cell & Gene, “The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers),” and their newly released white paper on BBLSA.com.Gene therapy has been talked about for many years, and it’s only in the past few years that we’ve begun to see some initial products make it to market. When many people think about gene therapies, they think they will be a curative treatment, but commercial positioning, pricing and the business model of gene therapies are still in flux.Topics in this podcast include:The scientific and commercial challenges of gene therapiesHow the space is evolving from a commercial standpoint -The complicated issue of deliveryThe investment of gene therapy & the outcome-based gene therapy business modelsRisk-sharing agreements, payment methodologies & pricing modelsThe unfolding future of gene therapiesCell & Gene guest columnBrendan Wang and Kyle O’Neil’s white paper on the Back Bay Life Science Advisors website. Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.